Compare Eli Lilly And Co (LLY) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Manulife Financial Corporation — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Manulife Financial Corporation trades at $42.52 (market cap $69.48B). The key difference: Eli Lilly And Co is far larger — about 15× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Manulife Financial Corporation for 119 Days on average.
| LLY | MFC | |
|---|---|---|
Market Cap | $1.04T | $69.48B |
Volume | 3,064,878 | 1,347,508 |
Sector | Health | Financials |
52-Week High | $1.28K | $44.77 |
52-Week Low | $799.57 | $31.64 |
Typical Hold Time | 93 Days | 119 Days |
Enterprise Value | $1.09T | $64.75B |
Dividend Yield | 0.59% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MFC trades at $42.33, up 1.58% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $53.01B in 2025 to projected $57.5B in 2026, with net income margins around 11%. Recent institutional investments from Bank of America and executive appointments signal confidence. However, the stock trades above the $34.24 consensus price target, suggesting limited near-term upside.
The outlook remains mixed with solid fundamentals but valuation concerns. Investment opportunity lies in continued Asia growth and insurance sales momentum, while risks include premium valuation and potential earnings volatility. Analyst consensus leans bullish with 57% buy ratings, but technical indicators warn of near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
